MX346530B - Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico. - Google Patents

Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico.

Info

Publication number
MX346530B
MX346530B MX2014009461A MX2014009461A MX346530B MX 346530 B MX346530 B MX 346530B MX 2014009461 A MX2014009461 A MX 2014009461A MX 2014009461 A MX2014009461 A MX 2014009461A MX 346530 B MX346530 B MX 346530B
Authority
MX
Mexico
Prior art keywords
preparation
ether compounds
formula
synthetic processes
aminocyclohexyl ether
Prior art date
Application number
MX2014009461A
Other languages
English (en)
Inventor
James Gee Ken Yee
Grace Jung
Doug Ta Hung Chou
Bertrand M C Plouvier
Original Assignee
Cardiome Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp filed Critical Cardiome Pharma Corp
Publication of MX346530B publication Critical patent/MX346530B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Esta invención está dirigida a síntesis estereoselectiva de los compuestos de la fórmula (I) o fórmula (II): (ver Fórmulas) o una sal, éster, amida, complejo, quelato, clatrato, solvato, polimorfo, estereoisómero, metabolito o profármaco farmacéuticamente aceptable de los mismos; en donde R3, R4 y R5 son como se define aquí; se sabe que los compuestos de la fórmula (I) y la fórmula (II) son útiles en el tratamiento de arritmias.
MX2014009461A 2005-06-15 2006-06-15 Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico. MX346530B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69098905P 2005-06-15 2005-06-15
US74824805P 2005-12-07 2005-12-07
PCT/US2006/023668 WO2006138673A2 (en) 2005-06-15 2006-06-15 Synthetic processes for the preparation of aminocyclohexyl ether compounds

Publications (1)

Publication Number Publication Date
MX346530B true MX346530B (es) 2017-03-22

Family

ID=37395936

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007016248A MX2007016248A (es) 2005-06-15 2006-06-15 Procedimiento sintetico para la preparacion de compuestos de eter aminociclohexilico.
MX2014009461A MX346530B (es) 2005-06-15 2006-06-15 Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2007016248A MX2007016248A (es) 2005-06-15 2006-06-15 Procedimiento sintetico para la preparacion de compuestos de eter aminociclohexilico.

Country Status (7)

Country Link
US (4) US7754897B2 (es)
EP (1) EP1915340B1 (es)
JP (1) JP5159616B2 (es)
BR (1) BRPI0612138B8 (es)
CA (1) CA2612375C (es)
MX (2) MX2007016248A (es)
WO (1) WO2006138673A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
CA2561733A1 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
JP5159314B2 (ja) * 2004-11-18 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の合成方法
EP1915340B1 (en) 2005-06-15 2013-08-07 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
EP2462933A1 (en) * 2007-05-04 2012-06-13 Cardiome Pharma Corp. Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
WO2010151551A1 (en) * 2009-06-23 2010-12-29 Medicinova, Inc. ENANTIOMERIC COMPOSITIONS OF 2-AMINO-1-(2-ISOPROPYLPYRAZOLO[1,5-a]PYRIDIN-3-YL)PROPAN-1-ONE AND RELATED METHODS
EP2605772B1 (en) 2010-08-16 2016-06-22 Cardiome International AG Process for preparing aminocyclohexyl ether compounds
EP2606139B1 (en) 2010-08-16 2015-07-15 Codexis, Inc. Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
CN115813902A (zh) 2012-01-20 2023-03-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
US10786470B2 (en) 2016-10-06 2020-09-29 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
CA3061340A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA710830A (en) 1965-06-01 Moser Paul Disodium and calcium salt of the calcium complex of 2-aminocyclohexyl 2'-aminoethyl ether-n,n,n',n'-tetraacetic acid
DE2860703D1 (en) 1977-12-01 1981-08-20 Bayer Ag Benzyl ethers of cyclic 1,2-diols, methods for their preparation and their use as herbicides
DE2753556A1 (de) 1977-12-01 1979-06-07 Bayer Ag Benzylaether von cyclischen 1,2-diolen, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4684728A (en) 1979-01-12 1987-08-04 Bayer Aktiengesellschaft Solubilizing biologically active compounds with reactive hydrogen atoms
DE3871343D1 (de) 1987-11-25 1992-06-25 American Cyanamid Co System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridin-calciumantagonisten.
DE3836917A1 (de) * 1988-10-29 1990-05-17 Bayer Ag Verfahren zur herstellung von cyclopropylamin
US5215919A (en) * 1991-02-25 1993-06-01 Takeda Chemical Industries, Ltd. Process for producing optically active 2-hydroxycycloalkanecarboxylic acid esters using microbially derived reductase
DE69535592T2 (de) * 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
PT801683E (pt) 1995-02-03 2002-09-30 Basf Ag Separacao de racematos de animais primarias e secundarias substituidas por heteroatomos por acilacao catalisada por enzimas
DE19523868A1 (de) * 1995-06-30 1997-01-02 Huels Chemische Werke Ag Verfahren zur Herstellung von Cyclopropanamin
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
ATE423130T1 (de) * 1997-10-08 2009-03-15 Isotechnika Inc Deuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agenzien
ATE260240T1 (de) 1998-04-01 2004-03-15 Nortran Pharmaceuticals Inc Aminocyclohexylverbindungen und deren verwendung
CA2346656A1 (en) 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
WO2000051981A1 (en) * 1999-03-04 2000-09-08 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
CA2311483A1 (en) 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
PL365694A1 (en) * 2000-06-28 2005-01-10 Teva Pharmaceutical Industries Ltd. Carvedilol
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
EP1291336A3 (en) * 2001-09-05 2003-10-08 Solvias AG Preparation of optically active alpha-hydroxyethers
JP2003250577A (ja) * 2001-12-27 2003-09-09 Sumitomo Chem Co Ltd ２‐ヒドロキシシクロアルカンカルボン酸エステルの製造方法
AU2003248647A1 (en) 2002-06-14 2003-12-31 Johnson Matthey Pharmaceutical Materials, Inc. Stereoselective synthesis of 1,2-disubstituted cycloalkyls
WO2004014973A2 (en) 2002-08-13 2004-02-19 Sirus Pharmaceuticals Ltd Biodegradable polymer
US7056540B2 (en) * 2002-10-29 2006-06-06 Council Of Scientific And Industrial Research Enzymatic process for the preparation of optically active alcohols from ketones using tuberous root Daucus carota
WO2004098525A2 (en) 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
ATE325789T1 (de) * 2003-05-02 2006-06-15 Cardiome Pharma Corp Aminocyclohexylether-verbindungen und deren verwendung
WO2005016242A2 (en) 2003-06-04 2005-02-24 Cardiome Pharma Corp. Synthetic process for trans-aminocyclohexyl ether compounds
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7977373B2 (en) * 2004-04-01 2011-07-12 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
CA2561733A1 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
US8058304B2 (en) * 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
JP5159314B2 (ja) * 2004-11-18 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の合成方法
EP1915340B1 (en) * 2005-06-15 2013-08-07 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
US20090069404A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched vernakalant

Also Published As

Publication number Publication date
US20120065408A1 (en) 2012-03-15
EP1915340B1 (en) 2013-08-07
WO2006138673A3 (en) 2007-03-22
US8344162B2 (en) 2013-01-01
EP1915340A2 (en) 2008-04-30
CA2612375A1 (en) 2006-12-28
BRPI0612138B1 (pt) 2021-03-16
WO2006138673A2 (en) 2006-12-28
US20120271057A9 (en) 2012-10-25
US20100217014A1 (en) 2010-08-26
MX2007016248A (es) 2008-03-07
US20130090483A1 (en) 2013-04-11
BRPI0612138A2 (pt) 2010-10-19
BRPI0612138B8 (pt) 2021-05-25
US20070015924A1 (en) 2007-01-18
JP2008543874A (ja) 2008-12-04
US8618311B2 (en) 2013-12-31
US7754897B2 (en) 2010-07-13
US8080673B2 (en) 2011-12-20
CA2612375C (en) 2013-08-06
JP5159616B2 (ja) 2013-03-06

Similar Documents

Publication Publication Date Title
MX346530B (es) Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico.
MY145466A (en) 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
TW200728307A (en) Novel spirochromanone derivatives
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
GB0719180D0 (en) New process
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
PH12014500947A1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
TW200734311A (en) New compounds
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MY148253A (en) Azaadamantane derivatives and methods of use
IL185419A0 (en) Improved process for the synthesis of enantiomeric indanylamine derivatives
WO2008055013A3 (en) 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
TW200833682A (en) Pharmaceutical compounds
MY162033A (en) New process for the synthesis of agomelatine
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
TNSN08244A1 (en) Process for the preparation of ferri-succinylcasein
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
SG170794A1 (en) Process for preparation of hiv protease inhibitors
WO2009121033A3 (en) Substituted nitrogen heterocycles and synthesis and uses thereof
EP2581372A4 (en) CYANOCHINOLINDERIVATE
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
WO2009005647A3 (en) Compounds and process to prepare chiral intermediates for synthesis of paroxetine